A device for fatigue, Raynaud's, and quality of life in scleroderma
Part of Heart & circulation, Skin clinical trials.
This trial tests if a device called Apollo can help reduce fatigue and Raynaud's symptoms and improve quality of life in people with scleroderma (systemic sclerosis). You would use the device at home and track your symptoms using a smartphone app.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with systemic sclerosis (scleroderma) and have a positive ANA test.
- You experience fatigue that scores at least 55 on a standard fatigue questionnaire.
- You have Raynaud's phenomenon with a severity score of 40 or higher.
- You have a smartphone (iPhone or Android) and use it regularly.
- You are willing to keep your current medications stable for 4 weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether people with systemic sclerosis (scleroderma) and pulmonary arterial hypertension (PAH) can safely monitor their heart health at home using a smartphone or other internet-connected device. If you have PAH and are comfortable using technology, this trial may help make care more convenient.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This study tests whether a person's own fat cells (processed into regenerative cells) can be injected into the hands to improve hand function and reduce skin thickening in systemic sclerosis (scleroderma). It’s designed for people whose hand problems are significant but not too severe.
This trial tests a new drug, GB261, for people with systemic sclerosis (a condition that causes thickening and hardening of the skin and can affect internal organs). It aims to see if it can help when other treatments haven't worked well enough.
This study tests a skin patch with botulinum toxin to ease blood vessel spasms in the fingers of people with scleroderma, which can cause pain and sores. It may help improve blood flow and reduce finger discomfort.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.